Effect of an Advanced Notification Letter on Screening Colonoscopy Participation

Overview

Participation in a primary screening colonoscopy programs remains low. Advanced notification letter has been shown to increase participation in colorectal cancer screening with fecal occult blood testing and to be cost effective compared to standard invitation. It is unknown whether advanced notification letter increases participation rate in primary colonoscopy screening program. We hypothesize that an Advance Notification Letter will have significant influence on participation in screening colonoscopy, comparing to standard invitation procedure and will thus result in higher efficiency of the program. This randomized controlled study aims to compare the participation rate in screening colonoscopy in response to advanced notification plus standard invitation letter and standard invitation letter alone. Material and methods: 6800 individuals aged 55-64 years will be drawn from the Population Registry and randomly assigned in a 1:1 ratio to the group invited for screening colonoscopy with advanced notification letter (send two weeks before standard invitation) plus standard invitation (send six weeks before planned screening colonoscopy) or to standard invitation only (send six weeks before planned screening colonoscopy). The sample size was calculated to detect 3% difference in participation rate between the groups (25% vs 28%) with 80% power.

Full Title of Study: “Participation in Screening Colonoscopy in Response to an Advanced Notification Letter Plus Standard Invitation Versus Standard Invitation Only – a Population-based Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Screening
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2014

Interventions

  • Other: Implementation of ANL
    • Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
  • Behavioral: No included ANL
    • Sending Standard Invitation only six weeks before planned screening colonoscopy

Arms, Groups and Cohorts

  • Experimental: Implementation of ANL
    • Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)
  • Active Comparator: No included ANL
    • Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy

Clinical Trial Outcome Measures

Primary Measures

  • Participation rate
    • Time Frame: three months after receiving invitation
    • A percentage of invitees who undergo the screening colonoscopy. The sample size was calculated to detect 3% difference in participation rate between the groups (25% vs 28%) with 80% power.

Secondary Measures

  • Response rate
    • Time Frame: three months after receiving invitation
    • Estimation of the invitees’ response rate to Standard Invitation and Advanced Notification Letter followed by Standard Invitation, before receiving Reminding Letter.

Participating in This Clinical Trial

Inclusion Criteria

  • all individuals aged 55-64 years living in the counties covered with the organized CRC screening program and assigned to invitation to screening colonoscopy in the year 2014 are eligible for the study. Exclusion Criteria:

  • message from neighbor/family/post office on death of screenee (not updated in Population Registry) – resident abroad (not updated in Population Registry) – return of unopened letter of invitation and/or reminder (address unknown) – diagnosis of CRC before the date of draw (not updated in the National Cancer Registry)

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: 64 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Maria Sklodowska-Curie National Research Institute of Oncology
  • Collaborator
    • Centre of Postgraduate Medical Education
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Karolina Janikowska, MD,MSc, Principal Investigator, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • Jaroslaw Regula, MD, PhD, Study Chair, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
    • Bartlomiej Kocot, Study Director, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.